Indian pharma companies like Dr Reddys, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.

Zydus Lifesciences announced that the USFDA granted Orphan Drug Designation to Usnoflast, a novel oral NLRP3 inhibitor, for ...

Zydus Lifesciences's Usnoflast receives Orphan Drug Designation from the USFDA for the treatment of Amyotrophic Lateral ...

Ahmedabad: Zydus, a discovery-based, global pharmaceutical company has announced that the U.S. Food and Drug Administration ...

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral ...

Zydus Lifesciences Ltd has been implicated in a recall of 23,304 bottles of Dapsone Gel 7.5%, a popular acne treatment ...

Zydus Lifesciences added 1.10% to Rs 987.60 after the company said that the USFDA had granted orphan drug designation (ODD) to Usnoflast, a novel oral NLRP3 inhibitor, for the treatment of amyotrophic ...

Zydus’ Usnoflast receives US FDA orphan drug designation to treat amyotrophic lateral sclerosis: Our Bureau, Mumbai Thursday, January 23, 2025, 12:15 Hrs [IST] Zydus, a leading, ...

Zydus Lifesciences announced that Usnoflast, a treatment for amyotrophic lateral sclerosis (ALS), has received Orphan Drug Designation from the US FDA. This designation supports the development of ...

Zydus' expanding product pipeline and strong fundamentals make it a compelling play in the pharmaceutical sector, the brokerage said.

Zydus Wellness Ltd announced that its subsidiary, Zydus Wellness Products Ltd, has received a GST demand of Rs 56.33 crore with interest and penalties from the tax authority. The demand relates to ...

CVS Caremark will add Zydus’ Zituvio and combination products to its template formulary starting January 1, 2025, Zydus Lifesciences Ltd said in a regulatory filing. Template formulary is a ...